Sitabaem Tablets 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Aprogen Biosciences Co., Ltd.
MFDS item code 202200227 · Approved 2022.01.12
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medicine is used as an adjunct to diet and exercise to improve blood sugar control in patients with type 2 diabetes. It is effective for patients who are starting diabetes medication for the first time or who have difficulty controlling blood sugar with metformin or sitagliptin alone. Additionally, it helps in treatment when sufficient blood sugar control is not achieved with combination therapy of metformin and sulfonylureas, or metformin and thiazolidinediones. It also improves blood sugar control when there is difficulty in achieving control with insulin and metformin combination therapy. In summary, this medication is effectively used to improve blood sugar control in patients with type 2 diabetes who have difficulty controlling blood sugar with various single or combination therapies.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each ingredient: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine is determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Because this medicine contains metformin, it should not be administered to patients with hepatic impairment (see Precautions for Use, 2. Do not administer to the following patients).
This medicine is used for the treatment of diabetes and contains two ingredients: sitagliptin and metformin. Caution is advised for hypersensitivity reactions when taking this medication. Rarely, severe allergic reactions may occur, and if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck appear, discontinue immediately and consult a doctor. Additionally, there is a risk of acute pancreatitis (inflammation of the pancreas), so if symptoms such as abdominal pain, nausea, vomiting, or fever occur, seek medical attention immediately. The metformin component can rarely cause lactic acidosis, a serious metabolic disorder, manifested by symptoms such as muscle pain, difficulty breathing, fatigue, and abdominal pain. Inform healthcare professionals immediately if these symptoms occur. This medication should not be used in patients with severely impaired renal function, acute heart failure, severe infections, or dehydration. Furthermore, it is advisable to temporarily discontinue this medication before and after tests using radiocontrast agents to protect kidney function and to resume only after kidney function returns to normal. It is safest for pregnant or breastfeeding women to avoid taking this medication. During treatment, regular monitoring of kidney function and blood tests should be done, especially for older adults or those with slightly impaired renal function, who should be monitored more often. Due to the risk of hypoglycemia, it is advisable to eat regularly and avoid prolonged fasting or excessive exercise. Hypoglycemia symptoms may occur when taken with other antidiabetic agents or insulin, so blood sugar levels should be monitored closely. The risk of lactic acidosis increases when taken with alcohol, so alcohol consumption should be avoided. It may be necessary to discontinue this medication for a certain period before and after surgery, so consult with healthcare professionals. If severe joint pain or skin blisters appear while taking this medication, inform a doctor immediately and receive treatment. Some patients may experience side effects such as diarrhea, nausea, vomiting, headache, upper respiratory tract infections, rhinitis, constipation, muscle pain, limb pain, back pain, itching, thrombocytopenia, peripheral edema, hypoglycemia, decreased appetite, pruritus, dizziness, and weight loss, and if symptoms are severe, consult with healthcare professionals. In case of overdose, seek emergency treatment immediately; if necessary, drug removal may be performed via dialysis. Finally, during the use of this medication, regular blood sugar testing and health condition monitoring should be carried out to ensure safe and effective treatment.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and it should be kept at room temperature between 1 to 30 degrees Celsius. This ensures the medication's efficacy is maintained and prevents deterioration.
Pink oval film-coated tablets
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Aprogen Biosciences Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.